undamentalytics Newsletter
Sign in

Axsome Therapeutics, Inc. revenue

Axsome Therapeutics, Inc.'s revenue was $638m in fiscal 2025, up 65.5% on the year before. Since fiscal 2022 ($50.0m) it has grown at a compound 133.7% a year. Over the last twelve months it was $865m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue50271386638865
Growth on the year before—+440.8%+42.5%+65.5%—
Gross profit45————
Gross margin89.6%————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $634M 99.3% ▲ 66.1%
Royalty and Milestone Revenue $4.7M 0.7% ▲ 17.0%

From Axsome Therapeutics, Inc.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Axsome Therapeutics, Inc. $865m 54.2% 57.0%
Supernus Pharmaceuticals, Inc. $865m 26.9% 12.3%
Corcept Therapeutics Inc $831m 16.0% 24.7%
Harmony Biosciences Holdings, Inc. $960m 24.3% 24.4%
ANI Pharmaceuticals Inc $978m 30.9% 34.6%
Pacira Biosciences, Inc. $746m 5.7% 3.7%

Compare with peers

Head to head: AXSM vs SUPNAXSM vs CORTAXSM vs HRMYANIP vs AXSM

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Axsome Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Axsome Therapeutics, Inc.